Medtronic Catapults Into Transcatheter Valve Market With Billion-Dollar Buys
This article was originally published in The Gray Sheet
Medtronic will enter the high-growth, minimally invasive aortic heart valve market through two acquisitions worth more than $1 billion
You may also be interested in...
The US Court of Appeals for the Federal Circuit upheld a Patent Trial & Appeals Board ruling against a doctor who claimed to be the true inventor of technology used in the CoreValve transcatheter aortic heart valve replacement device.
Direct Flow Medical hopes it May 7 appointment of Daniel Lemaitre as CEO will elevate its competitive game against larger players in the transcatheter aortic valve replacement market.
A settlement between the two companies dismissing all pending patent litigation related to transcatheter valve replacement technologies ends years of legal wrangling and ensures that the U.S. TAVR market will have at least two competitors.